medicaldevice-network.com
Cure8 news brief
Why This Matters
A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response without radiation.
This is development-stage news—it signals potential future options rather than an available test.
Who Should Pay Attention
Patients with Crohn’s disease and caregivers; gastroenterologists and radiologists; clinical researchers and industry observers.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
The FDA has granted fast track designation to Bracco Imaging’s ultrasound molecular contrast agent BR55 for detecting active bowel inflammation in Crohn’s disease.
BR55 is a microbubble agent that targets VEGFR2 to boost ultrasound signal and has completed Phase II studies; the company is preparing Phase III trials to test efficacy and safety for identifying angiogenesis and active inflammation. BR55 is being developed as a non-invasive, radiation-free way to image disease activity and monitor treatment response.
Fast track status means the FDA sees this as addressing an unmet need and may allow expedited development and review, but it is not an approval and more evidence from Phase III trials will be needed. This article reports regulatory and development-stage news from a medical device industry outlet.
It summarizes prior Phase II findings and company statements; it does not provide clinical guidance, specific trial results, or changes to standard care.
Keep In Mind
Fast track designation facilitates development and review but is not approval. The article summarizes company statements and Phase II findings; Phase III results and regulatory decisions will determine clinical use. No trial details or clinical performance metrics in Crohn’s are reported here.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedicaldevice-network.com
Indexed viaGoogle News
Source typeResearch news
PublishedFeb 7, 2025, 12:49 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA fast tracks Bracco’s BR55 for Crohn’s disease bowel inflammation detection
This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...
Monitoring Crohn's Disease After Surgery with Fecal Calprotectin - Physician's Weekly
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
Faecal Calprotectin Predicts Inflammation in Crohn’s Disease
Faecal calprotectin from ileostomy output could provide a non-invasive way to detect small-bowel inflammation after surgery, helping to guide monitoring and reduce reliance on invasive tests for postoperative Crohn’s...